Tumor neoantigen presentation

**Tumor neoantigen presentation** refers to the process by which peptides derived from tumor-specific mutations (neoantigens) are displayed on the surface of tumor or antigen-presenting cells via major histocompatibility complex (MHC) class I or II molecules, enabling recognition by T cells[3][4][5]. These neoantigens arise from somatic mutations, gene fusions, or abnormal splicing in cancer cells, and are distinct from self-proteins. Effective presentation of these molecules is essential for the immune system—particularly T cells—to identify and eliminate tumor cells, forming a mechanistic basis for current cancer immunotherapies like checkpoint inhibitors and personalized vaccines[5][4][2][7]. The diversity and quality of neoantigen presentation are closely linked to tumor mutational burden and can determine the success of immunotherapeutic interventions[9][7]. --- **Important note:** *"Tumor neoantigen presentation"* is not a single molecule, receptor, or druggable protein, but rather a **biological process or mechanism** involving multiple molecules (e.g., MHC, tumor antigens, TCRs, professional antigen-presenting cells) and pathways[3][4][5][7]. Thus, it should not be listed as a canonical molecular drug target but rather as a mechanism or process relevant to immunotherapy. - is_incorrect: true (not a single molecular target—should refer to a process; for structured databases, designate the actual molecules involved, such as MHC class I, MHC class II, antigen-processing machinery)

Other names

Neoantigen presentationTumor-specific neoantigen presentationNeoantigen display

Enhancement of neoantigen presentation increases T cell recognition and destruction of tumor cells Immune checkpoint inhibitors restore T cell function for recognizing neoantigen-presenting tumor cells Personalized vaccines stimulate T cell responses against patient-specific tumor neoantigens